LENZ Therapeutics, Inc.
For the period ended Dec 31, 2025. Filed Mar 24, 2026.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Mar 24, 2026
LENZ$4.29+22.6%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Balance Sheets
(in thousands, except for shares and par value)
| December 31, | ||
|---|---|---|
| 2025 | 2024 | |
| Assets | ||
| Current assets: | ||
| Cash and cash equivalents | $25,179 | $20,158 |
| Marketable securities | 267,168 | 188,872 |
| Accounts receivable, net | 329 | — |
| Inventory | 2,936 | — |
| Prepaid expenses and other current assets | 5,800 | 2,773 |
| Restricted cash | — | 114 |
| Total current assets | 301,412 | 211,917 |
| Property and equipment, net | 1,189 | 651 |
| Operating lease right-of-use asset | 734 | 1,338 |
| Other assets | 2,541 | 1,398 |
| Total assets | $305,876 | $215,304 |
| Liabilities and stockholders’ equity | ||
| Current liabilities: | ||
| Accounts payable | $4,167 | $4,257 |
| Accrued liabilities | 17,020 | 6,149 |
| Total current liabilities | 21,187 | 10,406 |
| Operating lease liability, net | 350 | 814 |
| Total liabilities | 21,537 | 11,220 |
| Commitments and contingencies (Note 8) | ||
| Stockholders' equity: | ||
| Preferred stock, par value of $0.00001 per share; 10,000,000 shares authorized at December 31, 2025 and 2024; no shares issues and outstanding at December 31, 2025 and 2024 | — | — |
| Common stock, par value of $0.00001 per share; 300,000,000 shares authorized at December 31, 2025 and 2024; 31,344,782 and 27,531,490 shares issued at December 31, 2025 and 2024, respectively; and 31,344,782 and 27,518,439 shares outstanding at December 31, 2025 and 2024, respectively | 1 | 1 |
| Additional paid-in capital | 511,237 | 348,901 |
| Accumulated deficit | (227,141) | (145,014) |
| Accumulated other comprehensive income | 242 | 196 |
| Total stockholders’ equity | 284,339 | 204,084 |
| Total liabilities and stockholders’ equity | $305,876 | $215,304 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.